UChicago Medicine has become the first medical center in Illinois to implant the Revi neuromodulation device, an exciting new ...

Researchers are a step closer to revolutionizing how doctors use radiotherapy to treat patients with muscle-invasive bladder ...

Ultimately, the real test lies in personal experience. With its unique formulation and positive user testimonials, FemiPro ...

Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...

Prostate cancer is a major health concern for men worldwide — often developing without any immediate warning signs. Catching ...

In response to the FDA request, there is a demonstrated duration of CR of 13.2% (9/68) at 540 days, 8.8% (6/68) at 630 days, 7.4% (5/68) at 720 days, 7.4% (5/68) at 900 days and 5.9% (4/68) at 1080 ...

Learn the signs that breast cancer may have progressed to metastasis, to ensure you get checked early and begin treatment as ...

A recent study published in the New England Journal of Medicine and found no significant survival benefit of extended ...

could predict how swiftly the illness will progress and suggest best treatment options, new research shows. The two symptoms ...

The SWOG S1011 randomized phase 3 trial found no significant improvement in disease-free or overall survival but a higher ...

The SWOG S1011 trial shows no survival benefit from extended lymphadenectomy in bladder cancer, revealing higher complications and mortality post-surgery.

We randomly assigned, in a 1:1 ratio, patients with localized muscle-invasive bladder cancer of clinical ... protocol-specified quality-control assessment involving 100 randomly selected patients ...